Abstract:
(1) Introduction: Chronic insomnia (CI) reduces quality of life and may trigger depression and cardiovascular diseases. The European Sleep Research Society recommends cognitive behavioural therapy (CBT-I) as the first-line treatment. Because a recent study in Switzerland demonstrated that this recommendation was inconsistently followed by primary care physicians, we hypothesised that pharmacists also deviate from these guidelines. The aim of this study is to describe current treatment practices for CI recommended by pharmacists in Switzerland, compare them to guidelines and examine their attitudes towards CBT-I. (2) Methods: A structured survey was sent to all the members of the Swiss Pharmacists Association, containing three clinical vignettes describing typical CI pharmacy clients. Treatments had to be prioritised. The prevalence of CI, and the pharmacists\' knowledge and interest in CBT-I were assessed. (3) Results: Of 1523 pharmacies, 123 pharmacists (8%) completed the survey. Despite large variations, valerian (96%), relaxation therapy (94%) and other phytotherapies (85%) were most recommended. Although most pharmacists did not know about CBT-I (72%) and only 10% had recommended it, most were very interested (64%) in education. Missing financial compensation hampers the recommendation of CBT-I. (4) Conclusions: Contrary to existing European guidelines, community pharmacists in Switzerland mostly recommended valerian, relaxation therapy and other phytotherapies for treating CI. This might be connected to the client\'s expectation of pharmacy services, e.g., medication dispensing. While pharmacists recommend sleep hygiene regularly, most did not know of CBT-I as an overarching concept but were willing to learn. Future studies should test the effects of dedicated training about CI and changes in the financial compensation for counselling for CI in pharmacies.
摘要:
(1)简介:慢性失眠(CI)会降低生活质量,并可能引发抑郁症和心血管疾病。欧洲睡眠研究协会推荐认知行为疗法(CBT-I)作为一线治疗。因为瑞士最近的一项研究表明,初级保健医生不一致地遵循这一建议,我们假设药剂师也偏离了这些指南.这项研究的目的是描述瑞士药剂师推荐的CI的当前治疗实践,将它们与指南进行比较,并检查他们对CBT-I的态度。(2)方法:向瑞士药剂师协会的所有成员发送了结构化调查,包含三个描述典型CI药房客户的临床插图。必须优先考虑治疗。评估了CI的患病率以及药剂师对CBT-I的知识和兴趣。(3)结果:1523家药店,123名药剂师(8%)完成了调查。尽管变化很大,缬草(96%),最推荐放松疗法(94%)和其他植物疗法(85%)。虽然大多数药剂师不知道CBT-I(72%),只有10%的人推荐它,大多数人对教育非常感兴趣(64%)。缺少经济补偿妨碍了CBT-I的建议。(4)结论:与现有的欧洲准则相反,瑞士的社区药剂师大多推荐缬草,放松疗法和其他用于治疗CI的植物疗法。这可能与客户对药房服务的期望有关,例如,药物分配。虽然药剂师建议定期睡眠卫生,大多数人不知道CBT-I是一个总体概念,但他们愿意学习。未来的研究应测试对CI的专门培训的影响以及药房中CI咨询的财务补偿的变化。